Helen Heyerdahl
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.
Journal: PloS one
Published: November 06, 2020
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003.
Journal: PloS one
Published: November 06, 2019
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 21, 2018
Realistic multi-cellular dosimetry for 177Lu-labelled antibodies: model and application.
Journal: Physics in medicine and biology
Published: September 13, 2016
Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts.
Journal: International journal of radiation oncology, biology, physics
Published: January 15, 2013
Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts.
Journal: Current radiopharmaceuticals
Published: March 24, 2012
Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.
Journal: Current radiopharmaceuticals
Published: March 19, 2012
Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
Journal: PloS one
Published: February 22, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026